Cantor Fitzgerald Forecasts UTHR FY2026 Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Cantor Fitzgerald issued their FY2026 EPS estimates for United Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biotechnology company will post earnings per share of $29.26 for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $405.00 target price on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same quarter last year, the company posted $6.17 EPS. United Therapeutics’s revenue for the quarter was up 17.2% on a year-over-year basis.

Several other analysts have also recently weighed in on UTHR. JPMorgan Chase & Co. decreased their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a research note on Thursday, May 1st. Bank of America raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price for the company in a research note on Monday, April 21st. Wall Street Zen lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. HC Wainwright reissued a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. Finally, Morgan Stanley increased their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 1st. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $393.00.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $328.40 on Tuesday. The company has a fifty day moving average price of $301.38 and a 200 day moving average price of $332.82. The stock has a market cap of $14.81 billion, a P/E ratio of 14.42, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics has a one year low of $266.98 and a one year high of $417.82.

Insider Transactions at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the transaction, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. This trade represents a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,500 shares of company stock valued at $16,923,950. 10.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Cerity Partners LLC grew its holdings in United Therapeutics by 30.4% during the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $4,098,000 after buying an additional 2,702 shares in the last quarter. Korea Investment CORP grew its stake in United Therapeutics by 6.2% in the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company’s stock valued at $13,863,000 after purchasing an additional 2,300 shares during the last quarter. Illumine Investment Management LLC acquired a new stake in United Therapeutics in the fourth quarter valued at approximately $3,015,000. ExodusPoint Capital Management LP purchased a new stake in United Therapeutics in the fourth quarter valued at about $1,899,000. Finally, Raymond James Financial Inc. purchased a new position in shares of United Therapeutics in the fourth quarter worth $18,257,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.